Try our Advanced Search for more refined results

US Coverage

Law360 Authority | Deep News & Analysis

Global Coverage

Law360 Pulse | The Business of Law

Mealeys

MLex

November 19, 2014

PAR PHARMACEUTICAL, INC. v. GLAXOSMITHKLINE LLC et al

View recent docket activity

Reflects complaints, answers, motions, orders and trial notes entered from Jan. 1, 2011.
Additional or older documents may be available in Pacer.

Coverage

  1. November 19, 2014

    Par Pharma Says Its New Drug Won't Rip Off GSK's Lamictal

    Par Pharmaceutical Inc. on Wednesday urged a Pennsylvania federal court to declare that its new drug doesn't infringe GlaxoSmithKline LLC's epilepsy and bipolar disorder treatment Lamictal, saying the U.S. Food and Drug Administration won't let Par market its drug until a generic version of Lamictal is released.

Parties

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Direct access to case information and documents.
  • All significant new filings across U.S. federal district courts, updated hourly on business days.
  • Full-text searches on all patent complaints in federal courts.
  • No-fee downloads of the complaints and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

View the parties now

Already a subscriber? Click here to login